Chronic exposure to asbestos enhances TGF-β1 production in the human adult T cell leukemia virus-immortalized T cell line MT-2

International Journal of Oncology

Volumn 45, Issue 6, 2014, Pages 2522-2532

  Maeda, Megumi ^a,b   Chen, Ying ^b,c   Hayashi, Hiroaki ^b   Kumagai Takei, Naoko ^b   Matsuzaki, Hidenori ^b   Lee, Suni ^b   Nishimura, Yasumitsu ^b   Otsuki, Takemi ^b  

^a OKAYAMA UNIVERSITY   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

^c CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Asbestos chrysotile; MAPK; SMAD

Indexed keywords

ASBESTOS; LIPOCORTIN 5; MITOGEN ACTIVATED PROTEIN KINASE P38; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BIOSYNTHESIS; CELL PROLIFERATION; CHEMICALLY INDUCED; DRUG EFFECTS; GENE SILENCING; GENETICS; HUMAN; IMMUNE SYSTEM; METABOLISM; PATHOLOGY; T CELL LEUKEMIA; TUMOR CELL LINE;

ADULT; ANNEXIN A5; APOPTOSIS; ASBESTOS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNE SYSTEM; LEUKEMIA-LYMPHOMA, ADULT T-CELL; P38 MITOGEN-ACTIVATED PROTEIN KINASES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84907702548     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2682     Document Type: Article

References (47)

1. Pan XL, Day HW, Wang W, Beckett LA and Schenker MB: Residential proximity to naturally occurring asbestos and mesothelioma risk in California. Am J Respir Crit Care Med 172:1019-1025, 2005.
2. Kurumatani N and Kumagai S: Mapping the risk of mesothelioma due to neighborhood asbestos exposure. Am J Respir Crit Care Med 178:624-629, 2008.
3. Heintz NH, Janssen-Heininger YM and Mossman BT: Asbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathways. Am J Respir Cell Mol Biol 42:133-139, 2010.
4. LaDou J, Castleman B, Frank A, et al: The case for a global ban on asbestos. Environ Health Perspect 118:897-901, 2010.
5. Ueki A, Yamaguchi M, Ueki H, et al: Polyclonal human T-cell activation by silicate in vitro. Immunology 82:332-335, 1994.
6. Aikoh T, Tomokuni A, Matsukii T, et al: Activation-induced cell death in human peripheral blood lymphocytes after stimulation with silicate in vitro. Int J Oncol 12:1355-1359, 1998.
7. Nishimura Y, Miura Y, Maeda M, et al: Impairment in cytotoxicity and expression of NK cell-activating receptors on human NK cells following exposure to asbestos fibers. Int J Immunopathol Pharmacol 22:579-590, 2009.
8. Nishimura Y, Maeda M, Kumagai N, Hayashi H, Miura Y and Otsuki T: Decrease in phosphorylation of ERK following decreased expression of NK cell-activating receptors in human NK cell line exposed to asbestos. Int J Immunopathol Pharmacol 22:879-888, 2009.
9. Kumagai-Takei N, Nishimura Y, Maeda M, et al: Effect of asbestos exposure on differentiation of cytotoxic T lymphocytes in mixed lymphocyte reaction of human peripheral blood mononuclear cells. Am J Respir Cell Mol Biol 49:28-36, 2013.
10. Nishimura Y, Maeda M, Kumagai-Takei N, et al: Altered functions of alveolar macrophages and NK cells involved in asbestos-related diseases. Environ Health Prev Med 18:198-204, 2013.
11. Miyoshi I, Kubonishi I, Yoshimoto S, et al: Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells. Nature 294:770-771, 1981.
12. Maeda M, Miura Y, Nishimura Y, et al: Immunological changes in mesothelioma patients and their experimental detection. Clin Med Circ Respirat Pulm Med 2:11-17, 2008.
13. Hyodoh F, Takata-Tomokuni A, Miura Y, et al: Inhibitory effects of anti-oxidants on apoptosis of a human polyclonal T-cell line, MT-2, induced by an asbestos, chrysotile-A. Scand J Immunol 61:442-448, 2005.
14. Miura Y, Nishimura Y, Katsuyama H, et al: Involvement of IL-10 and Bcl-2 in resistance against an asbestos-induced apoptosis of T cells. Apoptosis 11:1825-1835, 2006.
15. Nishimura Y, Miura Y, Maeda M, et al: Expression of the T cell receptor Vbeta repertoire in a human T cell resistant to asbestosinduced apoptosis and peripheral blood T cells from patients with silica and asbestos-related diseases. Int J Immunopathol Pharmacol 19:795-805, 2006.
16. Maeda M, Chen Y, Kumagai-Takei N, et al: Alteration of cytoskeletal molecules in a human T cell line caused by continuous exposure to chrysotile asbestos. Immunobiology 218:1184-1191, 2013.
17. Maeda M, Yamamoto S, Chen Y, et al: Resistance to asbestosinduced apoptosis with continuous exposure to crocidolite on a human T cell. Sci Total Environ 429:174-182, 2012.
18. Maeda M, Nishimura Y, Hayashi H, et al: Reduction of CXC chemokine receptor 3 in an in vitro model of continuous exposure to asbestos in a human T-cell line, MT-2. Am J Respir Cell Mol Biol 45:470-479, 2011.
19. + T cells exposed to asbestos or derived from asbestos-exposed patients. Am J Respir Cell Mol Biol: 795-803, 2011.
20. + adult T cell leukemia cells. Int Immunol 18:269-277, 2006.
21. + regulatory T cells in the human immune system. Nat Rev Immunol 10:490-500, 2010.
22. Flavell RA, Sanjabi S, Wrzesinski SH and Licona-Limon P: The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol: 554-567, 2010.
23. Kohyama N, Shinohara Y and Suzuki Y: Mineral phases and some reexamined characteristics of the International Union Against Cancer standard asbestos samples. Am J Ind Med 30:515-528, 1996.
24. Brummelkamp TR, Bernards R and Agami R: A system for stable expression of short interfering RNAs in mammalian cells. Science 296:550-553, 2002.
25. Bridge AJ, Pebernard S, Ducraux A, Nicoulaz AL and Iggo R: Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet 34:263-264, 2003.
26. Naldini L, Blomer U, Gallay P, et al: In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272:263-267, 1996.
27. Zufferey R, Nagy D, Mandel RJ, Naldini L and Trono D: Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 15:871-875, 1997.
28. Arnulf B, Villemain A, Nicot C, et al: Human T-cell lymphotropic virus oncoprotein Tax represses TGF-beta 1 signaling in human T cells via c-Jun. activation: a potential mechanism of HTLV-I leukemogenesis. Blood 100:4129-4138, 2002.
29. Li MO, Wan YY, Sanjabi S, Robertson AK and Flavell RA: Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 24:99-146, 2006.
30. Zhang W and Liu HT: MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res 12:9-18, 2002.
31. Letterio JJ: TGF-beta signaling in T cells: roles in lymphoid and epithelial neoplasia. Oncogene 24:5701-5712, 2005.
32. Klpl and checkpoint inhibitor Smad3 is involved in the induction of T cell tolerance. Nat Immunol 7:1157-1165, 2006.
33. Delisle JS, Giroux M, Boucher G, et al: The TGF-beta-Smad3 pathway inhibits CD28-dependenT cell growth and proliferation of CD4 T cells. Genes Immun 14:115-126, 2013.
34. Yoshimura A, Wakabayashi Y and Mori T: Cellular and molecular basis for the regulation of inflammation by TGF-beta. J Biochem 147:781-792, 2010.
35. Zhu H, Kavsak P, Abdollah S, Wrana JL and Thomsen GH: A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation. Nature 400:687-693, 1999.
36. Wrzesinski SH, Wan YY and Flavell RA: Transforming growth factor-beta and the immune response: implications for anticancer therapy. Clin Cancer Res 13:5262-5270, 2007.
37. Suzuki E, Kim S, Cheung HK, et al: A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Res 67:2351-2359, 2007.
38. Zou W: Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6:295-307, 2006.
39. Fujii M, Toyoda T, Nakanishi H, et al: TGF-beta synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth. J Exp Med 209:479-494, 2012.
40. Murakami S, Nishimura Y, Maeda M, et al: Cytokine alteration and speculated immunological pathophysiology in silicosis and asbestos-related diseases. Environ Health Prev Med 14:216-222, 2009.
41. Derynck R and Zhang YE: Smad-dependent and Smadindependent pathways in TGF-beta family signalling. Nature 425:577-584, 2003.
42. Brown KA, Pietenpol JA and Moses HL: A tale of two proteins: differential roles and regulation of Smad2 and Smad3 in TGF-beta signaling. J Cell Biochem 101:9-33, 2007.
43. Siegel PM and Massague J: Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 3:807-821, 2003.
44. Levy L and Hill CS: Alterations in components of the TGF-beta superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev 17:41-58, 2006.
45. Xiao YQ, Freire-de-Lima CG, Schiemann WP, Bratton DL, Vandivier RW and Henson PM: Transcriptional and translational regulation of TGF-beta production in response to apoptotic cells. J Immunol 181:3575-3585, 2008.
46. - T cells into iTreg. PLoS One 3: e3302, 2008.
47. Calabro L, Morra A, Fonsatti E, et al: Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol 14:1104-1111, 2013.